Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Steven R. Alberts

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5835-4122; OpenAlex author ID A5019214686. Sources: ClinicalTrials.gov.

Their work

Papers
8 (first author 1, last author 2)
Trials
2
Grants
0
Labs led
1
Collaborators
48
Papers, trials and grants by year

1999: 1 trial · 2000: none · 2001: 1 trial · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 8

  1. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16101861↗
  2. N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma. Last author DOI 10.1093/oncolo/oyac002↗
  3. Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2019.11.003↗
  4. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adeno… Last author DOI 10.1634/theoncologist.2018-0878↗
  5. EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. First author DOI 10.1016/j.gie.2016.11.014↗
  6. Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. Co-author DOI 10.1158/1078-0432.ccr-13-2024↗
  7. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Co-author DOI 10.1245/s10434-013-2886-9↗
  8. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. Co-author DOI 10.1200/jco.2011.34.8904↗

Trials 2

  1. Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas Study chair NCT00006467↗
  2. Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer Study chair NCT00004190↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thorvardur Ragnar Halfdanarson · 3 shared papers, 2019–2024 · strength 0.44
  2. George P. Kim · 2 shared papers, 2019–2022 · strength 0.27
  3. Robert R. McWilliams · 2 shared papers, 2020–2024 · strength 0.25
  4. Michael G. Haddock · 2 shared papers, 2017–2022 · strength 0.24
  5. Alexander Revzin · 1 shared paper, 2024 · strength 0.17
  6. Sani Haider Kizilbash · 1 shared paper, 2024 · strength 0.17
  7. Daniel H. Ahn · 1 shared paper, 2024 · strength 0.17
  8. Aakash P. Desai · 1 shared paper, 2024 · strength 0.17
  9. Alex A. Adjei · 1 shared paper, 2024 · strength 0.17
  10. Daheui Choi · 1 shared paper, 2024 · strength 0.17
  11. Aaron Scott Mansfield · 1 shared paper, 2024 · strength 0.17
  12. Hani M. Babiker · 1 shared paper, 2024 · strength 0.17
  13. Ryan Michael Carr · 1 shared paper, 2024 · strength 0.17
  14. Wen Wee Ma · 1 shared paper, 2024 · strength 0.17
  15. Tanios Bekaii‐Saab · 1 shared paper, 2024 · strength 0.17
  16. Amit Mahipal · 1 shared paper, 2024 · strength 0.17
  17. Ferga C. Gleeson · 2 shared papers, 2017–2020 · strength 0.15
  18. Naoki Takahashi · 2 shared papers, 2017–2020 · strength 0.15
  19. Michael L. Kendrick · 2 shared papers, 2017–2020 · strength 0.15
  20. Suresh T. Chari · 2 shared papers, 2017–2020 · strength 0.15
  21. Michael J. Levy · 2 shared papers, 2017–2020 · strength 0.15
  22. Thomas C. Smyrk · 1 shared paper, 2019 · strength 0.10
  23. Mark D. Topazian · 1 shared paper, 2020 · strength 0.09
  24. Thomas M. Malikowski · 1 shared paper, 2020 · strength 0.09
  25. Kenneth K. Wang · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.